| Revenue growth | FY26 +6% YoY; Q4 ex-gRevlimid +15.3% YoY. |
|---|---|
| Margins | EBITDA margin at 20.4%; guided >21% for FY27. |
| Demand visibility | Sustained momentum in regulated markets; stable volumes. |
| Management confidence | Bullish on US $2bn target and Europe €1bn base. |
Growth
FY26 revenue grew 6% YoY (9.5% ex-gRevlimid); Q4 FY26 revenue reached ₹8,853cr with Net Profit up 2% to ₹921cr.
Outlook
FY27 EBITDA margin guided north of 21%. US business aiming for $2bn revenue milestone near-term via Lannett acquisition.
Risks
Higher operating costs from power/fuel; seasonality in US sales; geopolitical issues; pricing pressures in biosimilars.
Earnings Call filed with BSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,680.80
- Market cap
- ₹97,621 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.8×Sector 47.4×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Regulatory Approval
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma Acquisition Worth ₹9.47 Cr
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
- Value
- ₹9.47 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
- Value
- ₹9.50 Cr
Aurobindo Pharma Business Update
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma Merger & Restructuring Worth ₹5 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.
- Value
- ₹5.00 Cr
Aurobindo Pharma Product Launch
Aurobindo Pharma's subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus® in the US. This marks the company's first commercialized product from its inhalation pipeline.